Diversity supplement for Oliver Viyar to receive research training in tissue engineering.

奥利弗·维亚尔 (Oliver Viyar) 接受组织工程研究培训的多样性补充。

• 批准号: 10075090
• 负责人: Stephanie Deshayes
• 金额: $ 2.47万
• 依托单位: TEMPO THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10075090
• 关键词: Admission activity; Alpha Particles; Animals; Biocompatible Materials; Biomedical Engineering; Biotechnology; Chemical Engineering; Development; Devices; Diabetic Foot Ulcer; Doctor of Philosophy; Engineering; Enrollment; Environment; Epithelial; Epithelium; Exposure to; Face; Family suidae; Filipino American; Formulation; Geometry; Goals; Health; Hydrogels; Impaired wound healing; Impairment; Industry; Inflammation; Inflammatory Response; Investigation; Lead; Light; Mechanics; Mentorship; Methods; Microspheres; Minority; Modeling; Multiple Wounds; Porifera; Porosity; Process; Production; Research; Research Assistant; Research Personnel; Research Training; Safety; Schools; Science; Scientist; Shapes; Site; Sterility; Supervision; Technology; Testing; Therapeutic; Tissue Engineering; Tissues; Universities; Variant; Vascularization; Virginia; Vocational Guidance; Work; base; career; diabetic; diabetic ulcer; healing; interest; manufacturing process; parent grant; particle; preclinical study; programs; regenerative; tissue regeneration; tissue support frame; wound

SUMMARY / ABSTRACT This supplement is submitted under the parent grant “MAP: a flowable, precision-engineered, and tunable tissue scaffold leveraging hyper-porous geometry to control inflammation and promote regenerative healing in diabetic wounds” and is for Oliver Viyar B.S., who will be the diversity investigator as a Filipino American minority on the application. Mr. Viyar is a post-baccalaureate researcher, who has demonstrated an interest in and wish to pursue research training in health-related sciences while applying for admission to graduate school. Mr. Voyar wishes to enroll in a PhD program for biomedical engineering with the ultimate goal to pursue his career as a lead scientist in the biotechnology industry. He seeks additional research training prior to applying for admission to PhD programs. Mr. Viyar received his Bachelor of Science degree in May 2019 in Chemical Engineering at the University of Virginia. After his graduation, Mr. Viyar began working as a research assistant at Tempo Therapeutics, Inc. The overall goal of the parent grant is to continue the development of the Microporous Annealed Particle (MAP) biomaterial technology for the treatment of impaired diabetic foot ulcers (DFUs). Our MAP materials are flowable (ease of application) and fill wounds of multiple shapes and sizes and convert to a hyper-porous sponge-like network in the wound site after exposure to LED white light. The hyper-porosity geometry promotes fast tissue ingrowth, early vascularization, and faster wound re-epithelialization when compared to leading decellularized tissue-based matrices, with minimal inflammatory response. We are employing specialized models of impaired wound healing in diabetic pigs to test a suite of three formulation variants already demonstrated in a preliminary healthy swine study. The optimal formulation of MAP that performs in slow healing environments and stimulates tissue regeneration will be selected for safety profiling and an Investigational Device Exemption (IDE) will be submitted at the end of the proposal. In this supplement and in regard to this parent grant, Mr. Viyar will be working directly under Dr. Deshayes’ supervision with the main goal to optimize one step of the manufacturing process for the fabrication of the hydrogel microspheres that compose the MAP product. The current manufacturing process faces some challenges of scalability and sterility. Therefore, Mr. Viyar will investigate the use of a static mixing method rather than a mechanical stirring method to fabricate the hydrogel microspheres in order to enhance the production scale and ease the aseptic process. Dr. Deshayes will provide him with both research mentorship and career guidance. In addition, Mr. Viyar will receive exposure to pre-clinical studies on large animals and regulatory process.

摘要/摘要 本补充材料是根据母基金“MAP：可流动、精密设计且可调节的 利用超多孔几何结构控制炎症并促进再生愈合的组织支架 糖尿病伤口”，是奥利弗·维亚尔（Oliver Viyar）理学学士，他将担任菲律宾裔美国人的多样性调查员 Viyar 先生是一名学士后研究员，他对应用程序表现出了兴趣。 并希望在申请研究生院时接受健康相关科学的研究培训。 Voyar 先生希望攻读生物医学工程博士学位课程，最终目标是追求他的 作为生物技术行业的首席科学家，他在申请之前寻求额外的研究培训。 Viyar 先生于 2019 年 5 月获得化学学士学位。 弗吉尼亚大学工程学毕业后，维亚尔先生开始担任研究助理。 在 Tempo 治疗公司 母公司资助的总体目标是继续开发微孔退火颗粒 (MAP) 生物材料技术用于治疗受损的糖尿病溃疡 (DFU) 我们的 MAP 材料是。 可流动（易于使用）并填充多种形状和尺寸的伤口，并转化为超多孔材料 暴露于 LED 白光后伤口部位的海绵状网络。 与相比，促进组织快速向内生长、早期血管化和更快的伤口上皮再生 领先的脱细胞组织基质，炎症反应最小。 糖尿病猪伤口愈合受损的专门模型，用于测试一套三种配方变体 已在一项健康猪的初步研究中证明了 MAP 的最佳配方。 将选择缓慢愈合的环境并刺激组织再生进行安全分析和 研究设备豁免 (IDE) 将在提案结束时提交。 在本补充文件和有关家长补助金中，Viyar 先生将直接在 Deshayes 博士的领导下工作 监督的主要目标是优化制造过程的一个步骤 构成 MAP 产品的水凝胶微球目前的制造工艺面临着一些问题。 因此，Viyar 先生将研究静态混合方法的使用。 而不是机械搅拌方法来制造水凝胶微球以增强 Deshayes 博士将为他提供生产规模和简化无菌流程的研究指导。 此外，维亚尔先生还将接触大型动物和动物的临床前研究。 监管流程。